P62745
PR
Gene name |
RHOB (ARH6, ARHB) |
Protein name |
Rho-related GTP-binding protein RhoB |
Names |
Rho cDNA clone 6, h6 |
Species |
Homo sapiens (Human) |
KEGG Pathway |
hsa:388 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
4 structures for P62745
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 2FV8 | X-ray | 190 A | A | 4-187 | PDB |
| 6HXU | X-ray | 119 A | A | 1-183 | PDB |
| 6SGE | X-ray | 150 A | A/C | 1-183 | PDB |
| AF-P62745-F1 | Predicted | AlphaFoldDB |
101 variants for P62745
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
|
rs774124299 CA1545439 |
3 | A>T | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA1545442 rs776997691 |
4 | I>M | No |
ClinGen ExAC gnomAD |
|
|
rs768817479 CA1545441 |
4 | I>V | No |
ClinGen ExAC gnomAD |
|
|
CA346229306 rs1400681652 |
11 | V>L | No |
ClinGen TOPMed |
|
|
CA346229321 rs1165459403 |
13 | D>G | No |
ClinGen TOPMed |
|
|
CA346229341 rs1331418969 |
16 | C>F | No |
ClinGen Ensembl |
|
| TCGA novel | 27 | K>L | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
| TCGA novel | 28 | D>H | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1427452665 CA346229430 |
29 | E>* | No |
ClinGen gnomAD |
|
|
rs1573124010 CA346229465 |
33 | V>G | No |
ClinGen Ensembl |
|
|
rs11541350 CA43891051 |
38 | V>F | No |
ClinGen Ensembl |
|
| TCGA novel | 40 | E>D | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA43891052 rs1002630226 |
43 | V>E | No |
ClinGen Ensembl |
|
|
CA346229653 rs1341957519 |
50 | G>D | No |
ClinGen TOPMed |
|
|
rs1347623585 CA346229647 |
50 | G>S | No |
ClinGen gnomAD |
|
|
CA1545463 rs763402300 |
52 | Q>* | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs1200482031 CA346229743 |
56 | A>S | No |
ClinGen gnomAD |
|
|
CA346229830 rs1573124102 |
64 | E>G | No |
ClinGen Ensembl |
|
|
rs1573124106 CA346229838 |
65 | D>G | No |
ClinGen Ensembl |
|
|
rs1171468075 CA346229842 |
66 | Y>D | No |
ClinGen TOPMed |
|
|
CA43891053 rs201421541 |
67 | D>A | No |
ClinGen Ensembl |
|
| TCGA novel | 68 | R>C | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs550750241 CA1545471 |
73 | S>C | No |
ClinGen 1000Genomes ExAC gnomAD |
|
|
CA346229950 rs1370678956 |
82 | M>I | No |
ClinGen gnomAD |
|
|
CA346229947 rs1247001677 |
82 | M>L | No |
ClinGen TOPMed |
|
|
CA1545472 rs757080270 |
82 | M>T | No |
ClinGen ExAC gnomAD |
|
| TCGA novel | 84 | F>C | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1303891767 CA346230003 |
87 | D>V | No |
ClinGen gnomAD |
|
|
rs750231833 CA1545474 |
88 | S>C | No |
ClinGen ExAC gnomAD |
|
|
rs994777412 CA43891056 COSM1015240 |
88 | S>N | Variant assessed as Somatic; impact. endometrium [NCI-TCGA, Cosmic] | No |
ClinGen cosmic curated NCI-TCGA TOPMed |
|
rs1266879398 CA346230035 |
89 | P>L | No |
ClinGen gnomAD |
|
|
rs1463207606 CA346230037 |
90 | D>N | No |
ClinGen gnomAD |
|
|
rs1463207606 CA346230040 |
90 | D>Y | No |
ClinGen gnomAD |
|
|
CA43891057 rs963666458 |
91 | S>L | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
ClinGen Ensembl NCI-TCGA |
|
rs748311060 CA1545477 |
95 | I>V | No |
ClinGen ExAC gnomAD |
|
|
rs529970135 CA1545478 |
96 | P>S | No |
ClinGen 1000Genomes ExAC gnomAD |
|
|
CA1545479 rs778091448 |
97 | E>D | No |
ClinGen ExAC gnomAD |
|
|
CA346230197 rs1477120342 |
101 | P>S | No |
ClinGen TOPMed gnomAD |
|
| TCGA novel | 102 | E>A | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA346230234 rs1573124241 |
103 | V>G | No |
ClinGen Ensembl |
|
|
CA346230284 rs1553303603 |
107 | C>S | No |
ClinGen Ensembl |
|
|
rs1326421885 CA346230329 |
112 | I>V | No |
ClinGen gnomAD |
|
|
rs1332182603 CA346230354 |
114 | L>P | No |
ClinGen TOPMed |
|
|
rs1320698179 CA346230377 |
116 | A>T | No |
ClinGen gnomAD |
|
| TCGA novel | 120 | D>Y | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs761431295 CA1545491 |
121 | L>M | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA346230484 rs761431295 |
121 | L>V | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs750285023 CA1545492 |
123 | S>G | No |
ClinGen ExAC gnomAD |
|
|
CA346230598 rs1415242880 |
126 | H>P | No |
ClinGen TOPMed |
|
|
CA1545493 rs137856773 |
126 | H>Q | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
|
CA1545494 rs766444400 |
127 | V>I | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA43891061 rs766444400 |
127 | V>L | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs1558281013 CA346230637 |
128 | R>H | No |
ClinGen Ensembl |
|
|
rs1179138210 CA346230665 |
130 | E>* | No |
ClinGen TOPMed |
|
|
CA1545498 rs777652531 |
132 | A>G | No |
ClinGen ExAC gnomAD |
|
|
rs1167248572 CA346230693 |
132 | A>P | No |
ClinGen gnomAD |
|
|
rs1167248572 CA346230691 |
132 | A>T | No |
ClinGen gnomAD |
|
|
rs749371378 CA1545499 |
133 | R>C | No |
ClinGen ExAC gnomAD |
|
|
rs879076076 CA43891063 |
134 | M>T | No |
ClinGen TOPMed |
|
|
rs1573124329 CA346230799 |
137 | E>D | No |
ClinGen Ensembl |
|
|
rs762014959 CA43891064 |
137 | E>K | No |
ClinGen Ensembl |
|
|
rs376095527 CA1545500 |
140 | R>L | No |
ClinGen ESP ExAC gnomAD |
|
|
rs1279564247 CA346230850 |
141 | T>A | No |
ClinGen gnomAD |
|
|
CA346230855 rs1377825440 |
141 | T>M | No |
ClinGen gnomAD |
|
|
rs1573124340 CA346230879 |
143 | D>A | No |
ClinGen Ensembl |
|
|
rs1226243351 CA346230936 |
147 | M>I | No |
ClinGen gnomAD |
|
|
CA346230946 rs1558281040 |
148 | A>S | No |
ClinGen Ensembl |
|
|
rs1291661597 CA346230955 |
148 | A>V | No |
ClinGen gnomAD |
|
|
rs975255411 CA43891065 |
149 | V>M | No |
ClinGen Ensembl |
|
|
CA346230978 rs1204121493 |
150 | R>C | No |
ClinGen TOPMed gnomAD |
|
|
rs1573124358 CA346230987 |
150 | R>H | No |
ClinGen Ensembl |
|
|
rs140945749 CA1545504 |
151 | I>S | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
CA346231016 rs1236966550 |
152 | Q>E | No |
ClinGen gnomAD |
|
|
CA1545506 rs769194384 |
154 | Y>C | No |
ClinGen ExAC gnomAD |
|
|
CA43891066 rs926807335 |
155 | D>N | No |
ClinGen TOPMed gnomAD |
|
|
rs1573124390 CA346231108 |
156 | Y>S | No |
ClinGen Ensembl |
|
| TCGA novel | 158 | E>A | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs765034772 CA1545509 |
160 | S>C | No |
ClinGen ExAC gnomAD |
|
|
rs761357342 CA1545508 |
160 | S>P | No |
ClinGen ExAC gnomAD |
|
| TCGA novel | 162 | K>R | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA1545511 rs762876812 |
163 | T>S | No |
ClinGen ExAC gnomAD |
|
|
rs1311239411 CA346231194 |
163 | T>S | No |
ClinGen TOPMed |
|
|
CA346231219 rs1295061094 |
166 | G>D | No |
ClinGen TOPMed gnomAD |
|
|
rs1277883236 CA346231229 |
168 | R>H | No |
ClinGen gnomAD |
|
|
CA43891069 rs945384144 |
169 | E>G | No |
ClinGen TOPMed |
|
|
rs754925693 CA1545514 |
170 | V>I | No |
ClinGen ExAC gnomAD |
|
|
CA346231249 rs1573124439 |
171 | F>C | No |
ClinGen Ensembl |
|
|
CA346231260 rs1238150863 |
173 | T>A | No |
ClinGen gnomAD |
|
|
rs1472952171 CA346231265 |
173 | T>M | No |
ClinGen TOPMed |
|
|
rs1208230246 CA346231271 |
174 | A>V | No |
ClinGen TOPMed |
|
|
rs1573124456 CA346231272 |
175 | T>P | No |
ClinGen Ensembl |
|
|
CA346231344 rs1287509106 |
181 | K>N | No |
ClinGen gnomAD |
|
|
CA346231351 rs1487044967 |
182 | R>H | No |
ClinGen gnomAD |
|
|
rs1193526492 CA346231402 |
185 | S>A | No |
ClinGen gnomAD |
|
|
CA346231413 rs1416686205 |
185 | S>Y | No |
ClinGen gnomAD |
|
|
CA346231432 rs1335541587 |
186 | Q>R | No |
ClinGen gnomAD |
|
|
CA346231486 rs1573124490 |
188 | G>A | No |
ClinGen Ensembl |
|
|
CA1545521 rs557099086 |
190 | I>M | No |
ClinGen 1000Genomes ExAC gnomAD |
|
|
rs769084741 CA346231645 |
196 | L>I | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA1545523 rs769084741 |
196 | L>V | No |
ClinGen ExAC TOPMed gnomAD |
|
| TCGA novel | 197 | L>C | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
No associated diseases with P62745
Functions
13 GO annotations of cellular component
| Name | Definition |
|---|---|
| cell cortex | The region of a cell that lies just beneath the plasma membrane and often, but not always, contains a network of actin filaments and associated proteins. |
| cell projection | A prolongation or process extending from a cell, e.g. a flagellum or axon. |
| cleavage furrow | The cleavage furrow is a plasma membrane invagination at the cell division site. The cleavage furrow begins as a shallow groove and eventually deepens to divide the cytoplasm. |
| cytoplasmic vesicle | A vesicle found in the cytoplasm of a cell. |
| cytoskeleton | A cellular structure that forms the internal framework of eukaryotic and prokaryotic cells. The cytoskeleton includes intermediate filaments, microfilaments, microtubules, the microtrabecular lattice, and other structures characterized by a polymeric filamentous nature and long-range order within the cell. The various elements of the cytoskeleton not only serve in the maintenance of cellular shape but also have roles in other cellular functions, including cellular movement, cell division, endocytosis, and movement of organelles. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| early endosome | A membrane-bounded organelle that receives incoming material from primary endocytic vesicles that have been generated by clathrin-dependent and clathrin-independent endocytosis; vesicles fuse with the early endosome to deliver cargo for sorting into recycling or degradation pathways. |
| endosome membrane | The lipid bilayer surrounding an endosome. |
| extracellular exosome | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. |
| focal adhesion | A cell-substrate junction that anchors the cell to the extracellular matrix and that forms a point of termination of actin filaments. In insects focal adhesion has also been referred to as hemi-adherens junction (HAJ). |
| late endosome membrane | The lipid bilayer surrounding a late endosome. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
4 GO annotations of molecular function
| Name | Definition |
|---|---|
| GDP binding | Binding to GDP, guanosine 5'-diphosphate. |
| GTP binding | Binding to GTP, guanosine triphosphate. |
| GTPase activity | Catalysis of the reaction: GTP + H2O = GDP + H+ + phosphate. |
| protein kinase binding | Binding to a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate. |
23 GO annotations of biological process
| Name | Definition |
|---|---|
| actin filament organization | A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments. Includes processes that control the spatial distribution of actin filaments, such as organizing filaments into meshworks, bundles, or other structures, as by cross-linking. |
| angiogenesis | Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels. |
| apoptotic process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. |
| cell adhesion | The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules. |
| cell differentiation | The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state. |
| cell migration | The controlled self-propelled movement of a cell from one site to a destination guided by molecular cues. Cell migration is a central process in the development and maintenance of multicellular organisms. |
| cellular response to hydrogen peroxide | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrogen peroxide (H2O2) stimulus. |
| cellular response to ionizing radiation | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ionizing radiation stimulus. Ionizing radiation is radiation with sufficient energy to remove electrons from atoms and may arise from spontaneous decay of unstable isotopes, resulting in alpha and beta particles and gamma rays. Ionizing radiation also includes X-rays. |
| cortical cytoskeleton organization | A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures in the cell cortex, i.e. just beneath the plasma membrane. |
| endosome to lysosome transport | The directed movement of substances from endosomes to lysosomes. |
| endothelial tube morphogenesis | The process in which the anatomical structures of a tube are generated and organized from an endothelium. Endothelium refers to the layer of cells lining blood vessels, lymphatics, the heart, and serous cavities, and is derived from bone marrow or mesoderm. Corneal endothelium is a special case, derived from neural crest cells. |
| establishment or maintenance of cell polarity | Any cellular process that results in the specification, formation or maintenance of anisotropic intracellular organization or cell growth patterns. |
| intracellular protein transport | The directed movement of proteins in a cell, including the movement of proteins between specific compartments or structures within a cell, such as organelles of a eukaryotic cell. |
| mitotic cytokinesis | A cell cycle process that results in the division of the cytoplasm of a cell after mitosis, resulting in the separation of the original cell into two daughter cells. |
| negative regulation of cell cycle | Any process that stops, prevents or reduces the rate or extent of progression through the cell cycle. |
| negative regulation of cell migration | Any process that stops, prevents, or reduces the frequency, rate or extent of cell migration. |
| positive regulation of angiogenesis | Any process that activates or increases angiogenesis. |
| positive regulation of apoptotic process | Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process. |
| positive regulation of endothelial cell migration | Any process that increases the rate, frequency, or extent of the orderly movement of an endothelial cell into the extracellular matrix to form an endothelium. |
| regulation of actin cytoskeleton organization | Any process that modulates the frequency, rate or extent of the formation, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments and their associated proteins. |
| regulation of cell migration | Any process that modulates the frequency, rate or extent of cell migration. |
| regulation of cell shape | Any process that modulates the surface configuration of a cell. |
| Rho protein signal transduction | The series of molecular signals within the cell that are mediated by a member of the Rho family of proteins switching to a GTP-bound active state. |
37 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q00246 | RHO4 | GTP-binding protein RHO4 | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast) | PR |
| Q17QI8 | Rhov | Rho-related GTP-binding protein RhoV | Bos taurus (Bovine) | PR |
| Q2HJ68 | RND1 | Rho-related GTP-binding protein Rho6 | Bos taurus (Bovine) | PR |
| P61585 | RHOA | Transforming protein RhoA | Bos taurus (Bovine) | PR |
| Q1RMJ6 | RHOC | Rho-related GTP-binding protein RhoC | Bos taurus (Bovine) | PR |
| Q3ZBW5 | RHOB | Rho-related GTP-binding protein RhoB | Bos taurus (Bovine) | PR |
| Q9PSX7 | RHOC | Rho-related GTP-binding protein RhoC | Gallus gallus (Chicken) | PR |
| P48148 | Rho1 | Ras-like GTP-binding protein Rho1 | Drosophila melanogaster (Fruit fly) | PR |
| O94955 | RHOBTB3 | Rho-related BTB domain-containing protein 3 | Homo sapiens (Human) | EV |
| O94844 | RHOBTB1 | Rho-related BTB domain-containing protein 1 | Homo sapiens (Human) | PR |
| P08134 | RHOC | Rho-related GTP-binding protein RhoC | Homo sapiens (Human) | PR |
| P61586 | RHOA | Transforming protein RhoA | Homo sapiens (Human) | PR |
| P61587 | RND3 | Rho-related GTP-binding protein RhoE | Homo sapiens (Human) | PR |
| Q92730 | RND1 | Rho-related GTP-binding protein Rho6 | Homo sapiens (Human) | PR |
| Q96L33 | RHOV | Rho-related GTP-binding protein RhoV | Homo sapiens (Human) | PR |
| Q8BLR7 | Rnd1 | Rho-related GTP-binding protein Rho6 | Mus musculus (Mouse) | PR |
| P61588 | Rnd3 | Rho-related GTP-binding protein RhoE | Mus musculus (Mouse) | PR |
| Q9DAK3 | Rhobtb1 | Rho-related BTB domain-containing protein 1 | Mus musculus (Mouse) | PR |
| Q9CTN4 | Rhobtb3 | Rho-related BTB domain-containing protein 3 | Mus musculus (Mouse) | SS |
| Q8VDU1 | Rhov | Rho-related GTP-binding protein RhoV | Mus musculus (Mouse) | PR |
| Q62159 | Rhoc | Rho-related GTP-binding protein RhoC | Mus musculus (Mouse) | PR |
| P62746 | Rhob | Rho-related GTP-binding protein RhoB | Mus musculus (Mouse) | PR |
| Q9QUI0 | Rhoa | Transforming protein RhoA | Mus musculus (Mouse) | PR |
| O77683 | RND3 | Rho-related GTP-binding protein RhoE | Sus scrofa (Pig) | PR |
| Q6SA80 | Rnd3 | Rho-related GTP-binding protein RhoE | Rattus norvegicus (Rat) | PR |
| Q9Z1Y0 | Rhov | Rho-related GTP-binding protein RhoV | Rattus norvegicus (Rat) | PR |
| P61589 | Rhoa | Transforming protein RhoA | Rattus norvegicus (Rat) | PR |
| P62747 | Rhob | Rho-related GTP-binding protein RhoB | Rattus norvegicus (Rat) | PR |
| Q9SSX0 | RAC1 | Rac-like GTP-binding protein 1 | Oryza sativa subsp japonica (Rice) | PR |
| Q6Z808 | RAC3 | Rac-like GTP-binding protein 3 | Oryza sativa subsp japonica (Rice) | PR |
| Q68Y52 | RAC2 | Rac-like GTP-binding protein 2 | Oryza sativa subsp japonica (Rice) | PR |
| Q67VP4 | RAC4 | Rac-like GTP-binding protein 4 | Oryza sativa subsp japonica (Rice) | PR |
| Q22038 | rho-1 | Ras-like GTP-binding protein rhoA | Caenorhabditis elegans | PR |
| Q9SU67 | ARAC8 | Rac-like GTP-binding protein ARAC8 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| O82480 | ARAC7 | Rac-like GTP-binding protein ARAC7 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q38903 | ARAC2 | Rac-like GTP-binding protein ARAC2 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| O82481 | ARAC10 | Rac-like GTP-binding protein ARAC10 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MAAIRKKLVV | VGDGACGKTC | LLIVFSKDEF | PEVYVPTVFE | NYVADIEVDG | KQVELALWDT |
| 70 | 80 | 90 | 100 | 110 | 120 |
| AGQEDYDRLR | PLSYPDTDVI | LMCFSVDSPD | SLENIPEKWV | PEVKHFCPNV | PIILVANKKD |
| 130 | 140 | 150 | 160 | 170 | 180 |
| LRSDEHVRTE | LARMKQEPVR | TDDGRAMAVR | IQAYDYLECS | AKTKEGVREV | FETATRAALQ |
| 190 | |||||
| KRYGSQNGCI | NCCKVL |